
    
      Study treatment will continue until the participant has completed 35 infusions (approximately
      2 years) of pembrolizumab treatment. All participants who stop study treatment with stable
      disease (SD) or better may be eligible for up to an additional ~1 year of study treatment if
      they progress after stopping study treatment from the initial treatment phase.
    
  